<?xml version="1.0" encoding="UTF-8" standalone="yes"?><Drugs><Drug><Id>22639</Id><DrugType><Type>Biological therapeutic</Type></DrugType><DrugTargetMaturity><TargetIndication><IndicationId>188</IndicationId><IndicationName>Inflammatory disease</IndicationName><MinPatentApplicationDate>2003-10-03T00:00:00Z</MinPatentApplicationDate><TargetId>PTGT-01192</TargetId><TargetName>Kallikrein</TargetName></TargetIndication><TargetIndication><IndicationId>156</IndicationId><IndicationName>Hereditary angioedema</IndicationName><MinPatentApplicationDate>2014-01-17T00:00:00Z</MinPatentApplicationDate><TargetId>PTGT-01192</TargetId><TargetName>Kallikrein</TargetName></TargetIndication><TargetIndication><IndicationId>188</IndicationId><IndicationName>Inflammatory disease</IndicationName><MinPatentApplicationDate>2013-10-25T00:00:00Z</MinPatentApplicationDate><TargetId>PTGT-03894</TargetId><TargetName>Complement C1s subcomponent</TargetName></TargetIndication><TargetIndication><IndicationId>57</IndicationId><IndicationName>Cardiovascular disease</IndicationName><MinPatentApplicationDate>2013-10-25T00:00:00Z</MinPatentApplicationDate><TargetId>PTGT-03894</TargetId><TargetName>Complement C1s subcomponent</TargetName></TargetIndication><TargetIndication><IndicationId>188</IndicationId><IndicationName>Inflammatory disease</IndicationName><MinPatentApplicationDate>2010-11-16T00:00:00Z</MinPatentApplicationDate><TargetId>PTGT-02904</TargetId><TargetName>Mannan-binding lectin serine protease</TargetName></TargetIndication><TargetIndication><IndicationId>3108</IndicationId><IndicationName>Renal injury</IndicationName><MinPatentApplicationDate>2018-09-14T00:00:00Z</MinPatentApplicationDate><TargetId>PTGT-03894</TargetId><TargetName>Complement C1s subcomponent</TargetName></TargetIndication><TargetIndication><IndicationId>250</IndicationId><IndicationName>Pancreatitis</IndicationName><MinPatentApplicationDate>1996-08-14T00:00:00Z</MinPatentApplicationDate><TargetId>PTGT-01192</TargetId><TargetName>Kallikrein</TargetName></TargetIndication><TargetIndication><IndicationId>65</IndicationId><IndicationName>Stroke</IndicationName><MinPatentApplicationDate>2008-12-09T00:00:00Z</MinPatentApplicationDate><TargetId>PTGT-03894</TargetId><TargetName>Complement C1s subcomponent</TargetName></TargetIndication><TargetIndication><IndicationId>1024</IndicationId><IndicationName>Reperfusion injury</IndicationName><MinPatentApplicationDate>2014-03-07T00:00:00Z</MinPatentApplicationDate><TargetId>PTGT-03894</TargetId><TargetName>Complement C1s subcomponent</TargetName></TargetIndication><TargetIndication><IndicationId>2989</IndicationId><IndicationName>Kidney transplant rejection</IndicationName><MinPatentApplicationDate>2014-11-21T00:00:00Z</MinPatentApplicationDate><TargetId>PTGT-03894</TargetId><TargetName>Complement C1s subcomponent</TargetName></TargetIndication><TargetIndication><IndicationId>57</IndicationId><IndicationName>Cardiovascular disease</IndicationName><MinPatentApplicationDate>1998-09-11T00:00:00Z</MinPatentApplicationDate><TargetId>PTGT-01192</TargetId><TargetName>Kallikrein</TargetName></TargetIndication><TargetIndication><IndicationId>156</IndicationId><IndicationName>Hereditary angioedema</IndicationName><MinPatentApplicationDate>1994-07-28T00:00:00Z</MinPatentApplicationDate><TargetId>PTGT-03894</TargetId><TargetName>Complement C1s subcomponent</TargetName></TargetIndication></DrugTargetMaturity><DevelopmentStatusCurrent><Row><Company id="1109567">Cytobioteck</Company><Country id="AR">Argentina</Country><DevelopmentStatus id="L" sortorder="15">Launched</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2017-11-27T00:00:00Z</StatusDate><SourceLink type="PR" id="1985443"/></Row><Row><Company id="1109567">Cytobioteck</Company><Country id="CO">Colombia</Country><DevelopmentStatus id="L" sortorder="15">Launched</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2017-11-27T00:00:00Z</StatusDate><SourceLink type="PR" id="1985443"/></Row><Row><Company id="1109567">Cytobioteck</Company><Country id="CR">Costa Rica</Country><DevelopmentStatus id="L" sortorder="15">Launched</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2017-11-27T00:00:00Z</StatusDate><SourceLink type="PR" id="1985443"/></Row><Row><Company id="1109567">Cytobioteck</Company><Country id="DO">Dominican Republic</Country><DevelopmentStatus id="L" sortorder="15">Launched</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2017-11-27T00:00:00Z</StatusDate><SourceLink type="PR" id="1985443"/></Row><Row><Company id="1109567">Cytobioteck</Company><Country id="PA">Panama</Country><DevelopmentStatus id="L" sortorder="15">Launched</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2017-11-27T00:00:00Z</StatusDate><SourceLink type="PR" id="1985443"/></Row><Row><Company id="1109567">Cytobioteck</Company><Country id="VE">Venezuela</Country><DevelopmentStatus id="L" sortorder="15">Launched</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2017-11-27T00:00:00Z</StatusDate><SourceLink type="PR" id="1985443"/></Row><Row><Company id="1068926">Hyupjin Corp</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="L" sortorder="15">Launched</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2016-04-26T00:00:00Z</StatusDate><SourceLink type="CORPORATE" id="1755864"/></Row><Row><Company id="26786">MegaPharm Ltd</Company><Country id="IL">Israel</Country><DevelopmentStatus id="L" sortorder="15">Launched</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2014-12-31T00:00:00Z</StatusDate><SourceLink type="CORPORATE" id="1696842"/></Row><Row><Company id="26342">Pharming NV</Company><Country id="DZ">Algeria</Country><DevelopmentStatus id="L" sortorder="15">Launched</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2017-05-24T00:00:00Z</StatusDate><SourceLink type="CORPORATE" id="1930536"/></Row><Row><Company id="26342">Pharming NV</Company><Country id="AD">Andorra</Country><DevelopmentStatus id="L" sortorder="15">Launched</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2017-05-24T00:00:00Z</StatusDate><SourceLink type="CORPORATE" id="1930536"/></Row><Row><Company id="26342">Pharming NV</Company><Country id="AT">Austria</Country><DevelopmentStatus id="L" sortorder="15">Launched</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2014-10-13T00:00:00Z</StatusDate><SourceLink type="PR" id="1696826"/></Row><Row><Company id="26342">Pharming NV</Company><Country id="BH">Bahrain</Country><DevelopmentStatus id="L" sortorder="15">Launched</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2017-05-24T00:00:00Z</StatusDate><SourceLink type="CORPORATE" id="1930536"/></Row><Row><Company id="26342">Pharming NV</Company><Country id="BE">Belgium</Country><DevelopmentStatus id="L" sortorder="15">Launched</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2017-05-24T00:00:00Z</StatusDate><SourceLink type="CORPORATE" id="1930536"/></Row><Row><Company id="26342">Pharming NV</Company><Country id="FR">France</Country><DevelopmentStatus id="L" sortorder="15">Launched</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2016-10-01T00:00:00Z</StatusDate><SourceLink type="PR" id="1884970"/></Row><Row><Company id="26342">Pharming NV</Company><Country id="DE">Germany</Country><DevelopmentStatus id="L" sortorder="15">Launched</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2014-10-13T00:00:00Z</StatusDate><SourceLink type="PR" id="1696826"/></Row><Row><Company id="26342">Pharming NV</Company><Country id="IE">Ireland</Country><DevelopmentStatus id="L" sortorder="15">Launched</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2017-05-24T00:00:00Z</StatusDate><SourceLink type="CORPORATE" id="1930536"/></Row><Row><Company id="26342">Pharming NV</Company><Country id="JO">Jordan</Country><DevelopmentStatus id="L" sortorder="15">Launched</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2017-05-24T00:00:00Z</StatusDate><SourceLink type="CORPORATE" id="1930536"/></Row><Row><Company id="26342">Pharming NV</Company><Country id="KW">Kuwait</Country><DevelopmentStatus id="L" sortorder="15">Launched</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2017-05-24T00:00:00Z</StatusDate><SourceLink type="CORPORATE" id="1930536"/></Row><Row><Company id="26342">Pharming NV</Company><Country id="LB">Lebanon</Country><DevelopmentStatus id="L" sortorder="15">Launched</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2017-05-24T00:00:00Z</StatusDate><SourceLink type="CORPORATE" id="1930536"/></Row><Row><Company id="26342">Pharming NV</Company><Country id="LU">Luxembourg</Country><DevelopmentStatus id="L" sortorder="15">Launched</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2017-05-24T00:00:00Z</StatusDate><SourceLink type="CORPORATE" id="1930536"/></Row><Row><Company id="26342">Pharming NV</Company><Country id="MA">Morocco</Country><DevelopmentStatus id="L" sortorder="15">Launched</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2017-05-24T00:00:00Z</StatusDate><SourceLink type="CORPORATE" id="1930536"/></Row><Row><Company id="26342">Pharming NV</Company><Country id="NL">Netherlands</Country><DevelopmentStatus id="L" sortorder="15">Launched</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2014-10-13T00:00:00Z</StatusDate><SourceLink type="PR" id="1696826"/></Row><Row><Company id="26342">Pharming NV</Company><Country id="OM">Oman</Country><DevelopmentStatus id="L" sortorder="15">Launched</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2017-05-24T00:00:00Z</StatusDate><SourceLink type="CORPORATE" id="1930536"/></Row><Row><Company id="26342">Pharming NV</Company><Country id="PT">Portugal</Country><DevelopmentStatus id="L" sortorder="15">Launched</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2017-05-24T00:00:00Z</StatusDate><SourceLink type="CORPORATE" id="1930536"/></Row><Row><Company id="26342">Pharming NV</Company><Country id="QA">Qatar</Country><DevelopmentStatus id="L" sortorder="15">Launched</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2017-05-24T00:00:00Z</StatusDate><SourceLink type="CORPORATE" id="1930536"/></Row><Row><Company id="26342">Pharming NV</Company><Country id="ES">Spain</Country><DevelopmentStatus id="L" sortorder="15">Launched</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2017-05-24T00:00:00Z</StatusDate><SourceLink type="CORPORATE" id="1930536"/></Row><Row><Company id="26342">Pharming NV</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="L" sortorder="15">Launched</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2017-05-24T00:00:00Z</StatusDate><SourceLink type="CORPORATE" id="1930536"/></Row><Row><Company id="26342">Pharming NV</Company><Country id="SY">Syria</Country><DevelopmentStatus id="L" sortorder="15">Launched</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2017-05-24T00:00:00Z</StatusDate><SourceLink type="CORPORATE" id="1930536"/></Row><Row><Company id="26342">Pharming NV</Company><Country id="TN">Tunisia</Country><DevelopmentStatus id="L" sortorder="15">Launched</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2017-05-24T00:00:00Z</StatusDate><SourceLink type="CORPORATE" id="1930536"/></Row><Row><Company id="26342">Pharming NV</Company><Country id="GB">UK</Country><DevelopmentStatus id="L" sortorder="15">Launched</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2016-10-01T00:00:00Z</StatusDate><SourceLink type="PR" id="1884970"/></Row><Row><Company id="26342">Pharming NV</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortorder="15">Launched</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2016-12-08T00:00:00Z</StatusDate><SourceLink type="PR" id="1884314"/></Row><Row><Company id="26342">Pharming NV</Company><Country id="AE">United Arab Emirates</Country><DevelopmentStatus id="L" sortorder="15">Launched</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2017-05-24T00:00:00Z</StatusDate><SourceLink type="CORPORATE" id="1930536"/></Row><Row><Company id="26342">Pharming NV</Company><Country id="YE">Yemen</Country><DevelopmentStatus id="L" sortorder="15">Launched</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2017-05-24T00:00:00Z</StatusDate><SourceLink type="CORPORATE" id="1930536"/></Row><Row><Company id="28921">Swedish Orphan Biovitrum AB</Company><Country id="AZ">Azerbaijan</Country><DevelopmentStatus id="L" sortorder="15">Launched</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2017-11-27T00:00:00Z</StatusDate><SourceLink type="PR" id="1985443"/></Row><Row><Company id="28921">Swedish Orphan Biovitrum AB</Company><Country id="BY">Belarus</Country><DevelopmentStatus id="L" sortorder="15">Launched</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2017-11-27T00:00:00Z</StatusDate><SourceLink type="PR" id="1985443"/></Row><Row><Company id="28921">Swedish Orphan Biovitrum AB</Company><Country id="DK">Denmark</Country><DevelopmentStatus id="L" sortorder="15">Launched</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2010-12-28T00:00:00Z</StatusDate><SourceLink type="PR" id="1158029"/></Row><Row><Company id="28921">Swedish Orphan Biovitrum AB</Company><Country id="EU">EU</Country><DevelopmentStatus id="L" sortorder="15">Launched</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2010-12-28T00:00:00Z</StatusDate><SourceLink type="PR" id="1158029"/></Row><Row><Company id="28921">Swedish Orphan Biovitrum AB</Company><Country id="GE">Georgia</Country><DevelopmentStatus id="L" sortorder="15">Launched</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2017-11-27T00:00:00Z</StatusDate><SourceLink type="PR" id="1985443"/></Row><Row><Company id="28921">Swedish Orphan Biovitrum AB</Company><Country id="IS">Iceland</Country><DevelopmentStatus id="L" sortorder="15">Launched</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2016-04-26T00:00:00Z</StatusDate><SourceLink type="CORPORATE" id="1755864"/></Row><Row><Company id="28921">Swedish Orphan Biovitrum AB</Company><Country id="KZ">Kazakhstan</Country><DevelopmentStatus id="L" sortorder="15">Launched</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2017-11-27T00:00:00Z</StatusDate><SourceLink type="PR" id="1985443"/></Row><Row><Company id="28921">Swedish Orphan Biovitrum AB</Company><Country id="LV">Latvia</Country><DevelopmentStatus id="L" sortorder="15">Launched</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2011-08-31T00:00:00Z</StatusDate><SourceLink type="PR" id="1218545"/></Row><Row><Company id="28921">Swedish Orphan Biovitrum AB</Company><Country id="LI">Liechtenstein</Country><DevelopmentStatus id="L" sortorder="15">Launched</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2016-04-26T00:00:00Z</StatusDate><SourceLink type="CORPORATE" id="1755864"/></Row><Row><Company id="28921">Swedish Orphan Biovitrum AB</Company><Country id="NO">Norway</Country><DevelopmentStatus id="L" sortorder="15">Launched</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2010-12-28T00:00:00Z</StatusDate><SourceLink type="PR" id="1158029"/></Row><Row><Company id="28921">Swedish Orphan Biovitrum AB</Company><Country id="RU">Russian Federation</Country><DevelopmentStatus id="L" sortorder="15">Launched</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2017-11-27T00:00:00Z</StatusDate><SourceLink type="PR" id="1985443"/></Row><Row><Company id="28921">Swedish Orphan Biovitrum AB</Company><Country id="RS">Serbia</Country><DevelopmentStatus id="L" sortorder="15">Launched</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2017-11-27T00:00:00Z</StatusDate><SourceLink type="PR" id="1985443"/></Row><Row><Company id="28921">Swedish Orphan Biovitrum AB</Company><Country id="SE">Sweden</Country><DevelopmentStatus id="L" sortorder="15">Launched</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2011-08-31T00:00:00Z</StatusDate><SourceLink type="PR" id="1218545"/></Row><Row><Company id="28921">Swedish Orphan Biovitrum AB</Company><Country id="UA">Ukraine</Country><DevelopmentStatus id="L" sortorder="15">Launched</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2017-11-27T00:00:00Z</StatusDate><SourceLink type="PR" id="1985443"/></Row><Row><Company id="26342">Pharming NV</Company><Country id="TR">Turkey</Country><DevelopmentStatus id="PR" sortorder="13">Pre-registration</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2010-03-18T00:00:00Z</StatusDate><SourceLink type="PR" id="1083845"/></Row><Row><Company id="26342">Pharming NV</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="C2" sortorder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3108">Renal injury</Indication><StatusDate>2017-01-18T00:00:00Z</StatusDate><SourceLink type="TRIALREG" id="1912341"/></Row><Row><Company id="26342">Pharming NV</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortorder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="250">Pancreatitis</Indication><StatusDate>2016-12-08T00:00:00Z</StatusDate><SourceLink type="PR" id="1884314"/></Row><Row><Company id="26342">Pharming NV</Company><Country id="NL">Netherlands</Country><DevelopmentStatus id="CU" sortorder="9">Clinical</DevelopmentStatus><Indication id="1259">Pre-eclampsia</Indication><StatusDate>2019-06-11T00:00:00Z</StatusDate><SourceLink type="PR" id="2161502"/></Row><Row><Company id="26342">Pharming NV</Company><Country id="US">US</Country><DevelopmentStatus id="CU" sortorder="9">Clinical</DevelopmentStatus><Indication id="1024">Reperfusion injury</Indication><StatusDate>2018-07-26T00:00:00Z</StatusDate><SourceLink type="PR" id="2057258"/></Row><Row><Company id="26342">Pharming NV</Company><Country id="AU">Australia</Country><DevelopmentStatus id="DR" sortorder="7">Discovery</DevelopmentStatus><Indication id="1259">Pre-eclampsia</Indication><StatusDate>2018-10-17T00:00:00Z</StatusDate><SourceLink type="PR" id="2116590"/></Row><Row><Company id="1068054">Transmedic Pte Ltd</Company><Country id="XI">South East Asia</Country><DevelopmentStatus id="DR" sortorder="7">Discovery</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2012-02-14T00:00:00Z</StatusDate><SourceLink type="PR" id="1262668"/></Row><Row><Company id="1038320">Eczacibasi Ilac Pazarlama AS</Company><Country id="TR">Turkey</Country><DevelopmentStatus id="DX" sortorder="4">Discontinued</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2017-05-24T00:00:00Z</StatusDate><SourceLink type="CORPORATE" id="1930536"/></Row><Row><Company id="14453">Hyland Immuno</Company><Country id="BE">Belgium</Country><DevelopmentStatus id="DX" sortorder="4">Discontinued</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2003-01-21T00:00:00Z</StatusDate><SourceLink type="CORPORATE" id="477062"/></Row><Row><Company id="14453">Hyland Immuno</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortorder="4">Discontinued</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2003-01-21T00:00:00Z</StatusDate><SourceLink type="CORPORATE" id="477062"/></Row><Row><Company id="16074">Laboratorios Dr Esteve SA</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DX" sortorder="4">Discontinued</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2011-08-29T00:00:00Z</StatusDate><SourceLink type="PR" id="1218277"/></Row><Row><Company id="24643">Salix Pharmaceuticals Ltd</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DX" sortorder="4">Discontinued</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2016-12-08T00:00:00Z</StatusDate><SourceLink type="PR" id="1884314"/></Row><Row><Company id="24643">Salix Pharmaceuticals Ltd</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="DX" sortorder="4">Discontinued</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2016-12-08T00:00:00Z</StatusDate><SourceLink type="PR" id="1884314"/></Row><Row><Company id="24643">Salix Pharmaceuticals Ltd</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortorder="4">Discontinued</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2016-12-08T00:00:00Z</StatusDate><SourceLink type="PR" id="1884314"/></Row><Row><Company id="24643">Salix Pharmaceuticals Ltd</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortorder="4">Discontinued</DevelopmentStatus><Indication id="2989">Kidney transplant rejection</Indication><StatusDate>2016-12-08T00:00:00Z</StatusDate><SourceLink type="PR" id="1884314"/></Row><Row><Company id="24643">Salix Pharmaceuticals Ltd</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortorder="4">Discontinued</DevelopmentStatus><Indication id="250">Pancreatitis</Indication><StatusDate>2016-12-08T00:00:00Z</StatusDate><SourceLink type="PR" id="1884314"/></Row><Row><Company id="28921">Swedish Orphan Biovitrum AB</Company><Country id="AT">Austria</Country><DevelopmentStatus id="DX" sortorder="4">Discontinued</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2014-10-13T00:00:00Z</StatusDate><SourceLink type="PR" id="1696826"/></Row><Row><Company id="28921">Swedish Orphan Biovitrum AB</Company><Country id="FR">France</Country><DevelopmentStatus id="DX" sortorder="4">Discontinued</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2016-10-01T00:00:00Z</StatusDate><SourceLink type="PR" id="1884970"/></Row><Row><Company id="28921">Swedish Orphan Biovitrum AB</Company><Country id="DE">Germany</Country><DevelopmentStatus id="DX" sortorder="4">Discontinued</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2014-10-13T00:00:00Z</StatusDate><SourceLink type="PR" id="1696826"/></Row><Row><Company id="28921">Swedish Orphan Biovitrum AB</Company><Country id="NL">Netherlands</Country><DevelopmentStatus id="DX" sortorder="4">Discontinued</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2014-10-13T00:00:00Z</StatusDate><SourceLink type="PR" id="1696826"/></Row><Row><Company id="28921">Swedish Orphan Biovitrum AB</Company><Country id="GB">UK</Country><DevelopmentStatus id="DX" sortorder="4">Discontinued</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2016-10-01T00:00:00Z</StatusDate><SourceLink type="PR" id="1884970"/></Row><Row><Company id="26342">Pharming NV</Company><Country id="NL">Netherlands</Country><DevelopmentStatus id="NDR" sortorder="3">No Development Reported</DevelopmentStatus><Indication id="57">Cardiovascular disease</Indication><StatusDate>2007-10-26T00:00:00Z</StatusDate></Row><Row><Company id="26342">Pharming NV</Company><Country id="CA">Canada</Country><DevelopmentStatus id="NDR" sortorder="3">No Development Reported</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2018-12-14T00:00:00Z</StatusDate></Row><Row><Company id="26342">Pharming NV</Company><Country id="CN">China</Country><DevelopmentStatus id="NDR" sortorder="3">No Development Reported</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2019-06-21T00:00:00Z</StatusDate></Row><Row><Company id="26342">Pharming NV</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="NDR" sortorder="3">No Development Reported</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2018-06-08T00:00:00Z</StatusDate></Row><Row><Company id="26342">Pharming NV</Company><Country id="NL">Netherlands</Country><DevelopmentStatus id="NDR" sortorder="3">No Development Reported</DevelopmentStatus><Indication id="188">Inflammatory disease</Indication><StatusDate>2007-10-26T00:00:00Z</StatusDate></Row><Row><Company id="26342">Pharming NV</Company><Country id="NL">Netherlands</Country><DevelopmentStatus id="NDR" sortorder="3">No Development Reported</DevelopmentStatus><Indication id="1024">Reperfusion injury</Indication><StatusDate>2009-05-05T00:00:00Z</StatusDate></Row><Row><Company id="26342">Pharming NV</Company><Country id="NL">Netherlands</Country><DevelopmentStatus id="NDR" sortorder="3">No Development Reported</DevelopmentStatus><Indication id="65">Stroke</Indication><StatusDate>2012-07-25T00:00:00Z</StatusDate></Row><Row><Company id="1010384">Shanghai Institute of Pharmaceutical Industry</Company><Country id="CN">China</Country><DevelopmentStatus id="NDR" sortorder="3">No Development Reported</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2019-06-21T00:00:00Z</StatusDate></Row><Row><Company id="26342">Pharming NV</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="OL" sortorder="1">Outlicensed</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2012-03-26T00:00:00Z</StatusDate><SourceLink type="PR" id="1274358"/></Row></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Row><Company id="24643">Salix Pharmaceuticals Ltd</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortorder="15">Launched</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2014-11-03T00:00:00Z</StatusDate><SourceLink type="PR" id="1607808"/></Row><Row><Company id="28921">Swedish Orphan Biovitrum AB</Company><Country id="AT">Austria</Country><DevelopmentStatus id="L" sortorder="15">Launched</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2014-10-13T00:00:00Z</StatusDate><SourceLink type="PR" id="1696826"/></Row><Row><Company id="28921">Swedish Orphan Biovitrum AB</Company><Country id="FR">France</Country><DevelopmentStatus id="L" sortorder="15">Launched</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2011-08-31T00:00:00Z</StatusDate><SourceLink type="PR" id="1218545"/></Row><Row><Company id="28921">Swedish Orphan Biovitrum AB</Company><Country id="DE">Germany</Country><DevelopmentStatus id="L" sortorder="15">Launched</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2011-08-31T00:00:00Z</StatusDate><SourceLink type="PR" id="1218545"/></Row><Row><Company id="28921">Swedish Orphan Biovitrum AB</Company><Country id="NL">Netherlands</Country><DevelopmentStatus id="L" sortorder="15">Launched</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2011-08-31T00:00:00Z</StatusDate><SourceLink type="PR" id="1218545"/></Row><Row><Company id="28921">Swedish Orphan Biovitrum AB</Company><Country id="GB">UK</Country><DevelopmentStatus id="L" sortorder="15">Launched</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2011-08-31T00:00:00Z</StatusDate><SourceLink type="PR" id="1218545"/></Row><Row><Company id="1068926">Hyupjin Corp</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="R" sortorder="14">Registered</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2015-12-21T00:00:00Z</StatusDate><SourceLink type="PR" id="1723098"/></Row><Row><Company id="16074">Laboratorios Dr Esteve SA</Company><Country id="EU">EU</Country><DevelopmentStatus id="R" sortorder="14">Registered</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2010-10-28T00:00:00Z</StatusDate><SourceLink type="PR" id="1142983"/></Row><Row><Company id="26342">Pharming NV</Company><Country id="IS">Iceland</Country><DevelopmentStatus id="R" sortorder="14">Registered</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2010-10-28T00:00:00Z</StatusDate><SourceLink type="PR" id="1142983"/></Row><Row><Company id="26342">Pharming NV</Company><Country id="IL">Israel</Country><DevelopmentStatus id="R" sortorder="14">Registered</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2014-01-15T00:00:00Z</StatusDate><SourceLink type="PR" id="1515653"/></Row><Row><Company id="26342">Pharming NV</Company><Country id="LI">Liechtenstein</Country><DevelopmentStatus id="R" sortorder="14">Registered</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2010-10-28T00:00:00Z</StatusDate><SourceLink type="PR" id="1142983"/></Row><Row><Company id="26342">Pharming NV</Company><Country id="NO">Norway</Country><DevelopmentStatus id="R" sortorder="14">Registered</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2010-10-28T00:00:00Z</StatusDate><SourceLink type="PR" id="1142983"/></Row><Row><Company id="26342">Pharming NV</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortorder="14">Registered</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2014-07-17T00:00:00Z</StatusDate><SourceLink type="PR" id="1577947"/></Row><Row><Company id="24643">Salix Pharmaceuticals Ltd</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortorder="14">Registered</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2014-07-17T00:00:00Z</StatusDate><SourceLink type="PR" id="1577947"/></Row><Row><Company id="28921">Swedish Orphan Biovitrum AB</Company><Country id="EU">EU</Country><DevelopmentStatus id="R" sortorder="14">Registered</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2010-10-28T00:00:00Z</StatusDate><SourceLink type="PR" id="1142983"/></Row><Row><Company id="28921">Swedish Orphan Biovitrum AB</Company><Country id="IS">Iceland</Country><DevelopmentStatus id="R" sortorder="14">Registered</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2010-10-28T00:00:00Z</StatusDate><SourceLink type="PR" id="1142983"/></Row><Row><Company id="28921">Swedish Orphan Biovitrum AB</Company><Country id="LI">Liechtenstein</Country><DevelopmentStatus id="R" sortorder="14">Registered</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2010-10-28T00:00:00Z</StatusDate><SourceLink type="PR" id="1142983"/></Row><Row><Company id="28921">Swedish Orphan Biovitrum AB</Company><Country id="NO">Norway</Country><DevelopmentStatus id="R" sortorder="14">Registered</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2010-10-28T00:00:00Z</StatusDate><SourceLink type="PR" id="1142983"/></Row><Row><Company id="16074">Laboratorios Dr Esteve SA</Company><Country id="EU">EU</Country><DevelopmentStatus id="PR" sortorder="13">Pre-registration</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2006-07-21T00:00:00Z</StatusDate><SourceLink type="PR" id="679518"/></Row><Row><Company id="26342">Pharming NV</Company><Country id="EU">EU</Country><DevelopmentStatus id="PR" sortorder="13">Pre-registration</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2006-07-21T00:00:00Z</StatusDate><SourceLink type="PR" id="679518"/></Row><Row><Company id="26342">Pharming NV</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortorder="13">Pre-registration</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2013-04-17T00:00:00Z</StatusDate><SourceLink type="PR" id="1405049"/></Row><Row><Company id="24643">Salix Pharmaceuticals Ltd</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortorder="13">Pre-registration</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2014-01-02T00:00:00Z</StatusDate><SourceLink type="PR" id="1512632"/></Row><Row><Company id="15957">Santarus Inc</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortorder="13">Pre-registration</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2013-04-17T00:00:00Z</StatusDate><SourceLink type="PR" id="1405049"/></Row><Row><Company id="28921">Swedish Orphan Biovitrum AB</Company><Country id="EU">EU</Country><DevelopmentStatus id="PR" sortorder="13">Pre-registration</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2010-04-15T00:00:00Z</StatusDate><SourceLink type="PR" id="1090974"/></Row><Row><Company id="16074">Laboratorios Dr Esteve SA</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C3" sortorder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2004-07-07T00:00:00Z</StatusDate><SourceLink type="PR" id="547967"/></Row><Row><Company id="26342">Pharming NV</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C3" sortorder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2004-07-07T00:00:00Z</StatusDate><SourceLink type="PR" id="547967"/></Row><Row><Company id="26342">Pharming NV</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortorder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2005-05-06T00:00:00Z</StatusDate><SourceLink type="PR" id="599963"/></Row><Row><Company id="15957">Santarus Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortorder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2011-02-22T00:00:00Z</StatusDate><SourceLink type="CORPORATE" id="1269430"/></Row><Row><Company id="26342">Pharming NV</Company><Country id="BE">Belgium</Country><DevelopmentStatus id="C2" sortorder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2003-01-07T00:00:00Z</StatusDate><SourceLink type="CORPORATE" id="475585"/></Row><Row><Company id="26342">Pharming NV</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C2" sortorder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2015-01-09T00:00:00Z</StatusDate><SourceLink type="PR" id="1625306"/></Row><Row><Company id="26342">Pharming NV</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortorder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="2989">Kidney transplant rejection</Indication><StatusDate>2010-11-08T00:00:00Z</StatusDate><SourceLink type="PR" id="1146331"/></Row><Row><Company id="15957">Santarus Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortorder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="2989">Kidney transplant rejection</Indication><StatusDate>2010-11-08T00:00:00Z</StatusDate><SourceLink type="PR" id="1146331"/></Row><Row><Company id="14453">Hyland Immuno</Company><Country id="BE">Belgium</Country><DevelopmentStatus id="C1" sortorder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2001-03-12T00:00:00Z</StatusDate><SourceLink type="PR" id="401486"/></Row><Row><Company id="14453">Hyland Immuno</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortorder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2001-03-12T00:00:00Z</StatusDate><SourceLink type="PR" id="401486"/></Row><Row><Company id="26342">Pharming NV</Company><Country id="BE">Belgium</Country><DevelopmentStatus id="C1" sortorder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2001-03-12T00:00:00Z</StatusDate><SourceLink type="PR" id="401486"/></Row><Row><Company id="24643">Salix Pharmaceuticals Ltd</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortorder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="250">Pancreatitis</Indication><StatusDate>2014-01-02T00:00:00Z</StatusDate><SourceLink type="PR" id="1512632"/></Row><Row><Company id="15957">Santarus Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortorder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="250">Pancreatitis</Indication><StatusDate>2013-04-11T00:00:00Z</StatusDate><SourceLink type="CORPORATE" id="1434839"/></Row><Row><Company id="26342">Pharming NV</Company><Country id="US">US</Country><DevelopmentStatus id="CU" sortorder="9">Clinical</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2005-03-09T00:00:00Z</StatusDate><SourceLink type="PR" id="588950"/></Row><Row><Company id="1109567">Cytobioteck</Company><Country id="AR">Argentina</Country><DevelopmentStatus id="DR" sortorder="7">Discovery</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2016-02-09T00:00:00Z</StatusDate><SourceLink type="PR" id="1734288"/></Row><Row><Company id="1109567">Cytobioteck</Company><Country id="CO">Colombia</Country><DevelopmentStatus id="DR" sortorder="7">Discovery</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2015-05-25T00:00:00Z</StatusDate><SourceLink type="PR" id="1663014"/></Row><Row><Company id="1109567">Cytobioteck</Company><Country id="CR">Costa Rica</Country><DevelopmentStatus id="DR" sortorder="7">Discovery</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2016-02-09T00:00:00Z</StatusDate><SourceLink type="PR" id="1734288"/></Row><Row><Company id="1109567">Cytobioteck</Company><Country id="DO">Dominican Republic</Country><DevelopmentStatus id="DR" sortorder="7">Discovery</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2016-02-09T00:00:00Z</StatusDate><SourceLink type="PR" id="1734288"/></Row><Row><Company id="1109567">Cytobioteck</Company><Country id="PA">Panama</Country><DevelopmentStatus id="DR" sortorder="7">Discovery</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2016-02-09T00:00:00Z</StatusDate><SourceLink type="PR" id="1734288"/></Row><Row><Company id="1109567">Cytobioteck</Company><Country id="VE">Venezuela</Country><DevelopmentStatus id="DR" sortorder="7">Discovery</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2015-05-25T00:00:00Z</StatusDate><SourceLink type="PR" id="1663014"/></Row><Row><Company id="1038320">Eczacibasi Ilac Pazarlama AS</Company><Country id="TR">Turkey</Country><DevelopmentStatus id="DR" sortorder="7">Discovery</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2008-03-25T00:00:00Z</StatusDate><SourceLink type="PR" id="889010"/></Row><Row><Company id="14453">Hyland Immuno</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortorder="7">Discovery</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2000-03-22T00:00:00Z</StatusDate><SourceLink type="PR" id="360393"/></Row><Row><Company id="1068926">Hyupjin Corp</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="DR" sortorder="7">Discovery</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2012-03-26T00:00:00Z</StatusDate><SourceLink type="PR" id="1274358"/></Row><Row><Company id="16074">Laboratorios Dr Esteve SA</Company><Country id="ES">Spain</Country><DevelopmentStatus id="DR" sortorder="7">Discovery</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2004-06-30T00:00:00Z</StatusDate><SourceLink type="PR" id="547967"/></Row><Row><Company id="26786">MegaPharm Ltd</Company><Country id="IL">Israel</Country><DevelopmentStatus id="DR" sortorder="7">Discovery</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2011-06-07T00:00:00Z</StatusDate><SourceLink type="PR" id="1197987"/></Row><Row><Company id="26342">Pharming NV</Company><Country id="NL">Netherlands</Country><DevelopmentStatus id="DR" sortorder="7">Discovery</DevelopmentStatus><Indication id="57">Cardiovascular disease</Indication><StatusDate>2005-02-24T00:00:00Z</StatusDate><SourceLink type="PR" id="586887"/></Row><Row><Company id="26342">Pharming NV</Company><Country id="DZ">Algeria</Country><DevelopmentStatus id="DR" sortorder="7">Discovery</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2016-10-01T00:00:00Z</StatusDate><SourceLink type="PR" id="1884970"/></Row><Row><Company id="26342">Pharming NV</Company><Country id="AD">Andorra</Country><DevelopmentStatus id="DR" sortorder="7">Discovery</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2016-10-01T00:00:00Z</StatusDate><SourceLink type="PR" id="1884970"/></Row><Row><Company id="26342">Pharming NV</Company><Country id="BH">Bahrain</Country><DevelopmentStatus id="DR" sortorder="7">Discovery</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2016-10-01T00:00:00Z</StatusDate><SourceLink type="PR" id="1884970"/></Row><Row><Company id="26342">Pharming NV</Company><Country id="BE">Belgium</Country><DevelopmentStatus id="DR" sortorder="7">Discovery</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>1999-03-19T17:05:40Z</StatusDate><SourceLink type="PR" id="317961"/></Row><Row><Company id="26342">Pharming NV</Company><Country id="CN">China</Country><DevelopmentStatus id="DR" sortorder="7">Discovery</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2014-12-30T00:00:00Z</StatusDate><SourceLink type="OTHER" id="1623768"/></Row><Row><Company id="26342">Pharming NV</Company><Country id="IE">Ireland</Country><DevelopmentStatus id="DR" sortorder="7">Discovery</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2016-10-01T00:00:00Z</StatusDate><SourceLink type="PR" id="1884970"/></Row><Row><Company id="26342">Pharming NV</Company><Country id="JO">Jordan</Country><DevelopmentStatus id="DR" sortorder="7">Discovery</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2016-10-01T00:00:00Z</StatusDate><SourceLink type="PR" id="1884970"/></Row><Row><Company id="26342">Pharming NV</Company><Country id="KW">Kuwait</Country><DevelopmentStatus id="DR" sortorder="7">Discovery</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2016-10-01T00:00:00Z</StatusDate><SourceLink type="PR" id="1884970"/></Row><Row><Company id="26342">Pharming NV</Company><Country id="LB">Lebanon</Country><DevelopmentStatus id="DR" sortorder="7">Discovery</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2016-10-01T00:00:00Z</StatusDate><SourceLink type="PR" id="1884970"/></Row><Row><Company id="26342">Pharming NV</Company><Country id="LU">Luxembourg</Country><DevelopmentStatus id="DR" sortorder="7">Discovery</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2016-10-01T00:00:00Z</StatusDate><SourceLink type="PR" id="1884970"/></Row><Row><Company id="26342">Pharming NV</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="DR" sortorder="7">Discovery</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2016-12-08T00:00:00Z</StatusDate><SourceLink type="PR" id="1884314"/></Row><Row><Company id="26342">Pharming NV</Company><Country id="MA">Morocco</Country><DevelopmentStatus id="DR" sortorder="7">Discovery</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2016-10-01T00:00:00Z</StatusDate><SourceLink type="PR" id="1884970"/></Row><Row><Company id="26342">Pharming NV</Company><Country id="NL">Netherlands</Country><DevelopmentStatus id="DR" sortorder="7">Discovery</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2007-11-05T00:00:00Z</StatusDate><SourceLink type="OTHER" id="848209"/></Row><Row><Company id="26342">Pharming NV</Company><Country id="OM">Oman</Country><DevelopmentStatus id="DR" sortorder="7">Discovery</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2016-10-01T00:00:00Z</StatusDate><SourceLink type="PR" id="1884970"/></Row><Row><Company id="26342">Pharming NV</Company><Country id="PT">Portugal</Country><DevelopmentStatus id="DR" sortorder="7">Discovery</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2016-10-01T00:00:00Z</StatusDate><SourceLink type="PR" id="1884970"/></Row><Row><Company id="26342">Pharming NV</Company><Country id="QA">Qatar</Country><DevelopmentStatus id="DR" sortorder="7">Discovery</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2016-10-01T00:00:00Z</StatusDate><SourceLink type="PR" id="1884970"/></Row><Row><Company id="26342">Pharming NV</Company><Country id="ES">Spain</Country><DevelopmentStatus id="DR" sortorder="7">Discovery</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2016-10-01T00:00:00Z</StatusDate><SourceLink type="PR" id="1884970"/></Row><Row><Company id="26342">Pharming NV</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="DR" sortorder="7">Discovery</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2016-10-01T00:00:00Z</StatusDate><SourceLink type="PR" id="1884970"/></Row><Row><Company id="26342">Pharming NV</Company><Country id="SY">Syria</Country><DevelopmentStatus id="DR" sortorder="7">Discovery</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2016-10-01T00:00:00Z</StatusDate><SourceLink type="PR" id="1884970"/></Row><Row><Company id="26342">Pharming NV</Company><Country id="TN">Tunisia</Country><DevelopmentStatus id="DR" sortorder="7">Discovery</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2016-10-01T00:00:00Z</StatusDate><SourceLink type="PR" id="1884970"/></Row><Row><Company id="26342">Pharming NV</Company><Country id="AE">United Arab Emirates</Country><DevelopmentStatus id="DR" sortorder="7">Discovery</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2016-10-01T00:00:00Z</StatusDate><SourceLink type="PR" id="1884970"/></Row><Row><Company id="26342">Pharming NV</Company><Country id="YE">Yemen</Country><DevelopmentStatus id="DR" sortorder="7">Discovery</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2016-10-01T00:00:00Z</StatusDate><SourceLink type="PR" id="1884970"/></Row><Row><Company id="26342">Pharming NV</Company><Country id="NL">Netherlands</Country><DevelopmentStatus id="DR" sortorder="7">Discovery</DevelopmentStatus><Indication id="188">Inflammatory disease</Indication><StatusDate>2005-02-24T00:00:00Z</StatusDate><SourceLink type="PR" id="586887"/></Row><Row><Company id="26342">Pharming NV</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortorder="7">Discovery</DevelopmentStatus><Indication id="2989">Kidney transplant rejection</Indication><StatusDate>2008-09-03T00:00:00Z</StatusDate><SourceLink type="PR" id="939943"/></Row><Row><Company id="26342">Pharming NV</Company><Country id="BE">Belgium</Country><DevelopmentStatus id="DR" sortorder="7">Discovery</DevelopmentStatus><Indication id="1259">Pre-eclampsia</Indication><StatusDate>2018-07-26T00:00:00Z</StatusDate><SourceLink type="PR" id="2057258"/></Row><Row><Company id="26342">Pharming NV</Company><Country id="NL">Netherlands</Country><DevelopmentStatus id="DR" sortorder="7">Discovery</DevelopmentStatus><Indication id="1259">Pre-eclampsia</Indication><StatusDate>2018-09-30T00:00:00Z</StatusDate><SourceLink type="PR" id="2161502"/></Row><Row><Company id="26342">Pharming NV</Company><Country id="NL">Netherlands</Country><DevelopmentStatus id="DR" sortorder="7">Discovery</DevelopmentStatus><Indication id="1024">Reperfusion injury</Indication><StatusDate>2007-11-05T00:00:00Z</StatusDate><SourceLink type="OTHER" id="848209"/></Row><Row><Company id="26342">Pharming NV</Company><Country id="NL">Netherlands</Country><DevelopmentStatus id="DR" sortorder="7">Discovery</DevelopmentStatus><Indication id="65">Stroke</Indication><StatusDate>2007-11-05T00:00:00Z</StatusDate><SourceLink type="OTHER" id="848209"/></Row><Row><Company id="24643">Salix Pharmaceuticals Ltd</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DR" sortorder="7">Discovery</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2014-01-02T00:00:00Z</StatusDate><SourceLink type="PR" id="1512632"/></Row><Row><Company id="24643">Salix Pharmaceuticals Ltd</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="DR" sortorder="7">Discovery</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2014-01-02T00:00:00Z</StatusDate><SourceLink type="PR" id="1512632"/></Row><Row><Company id="24643">Salix Pharmaceuticals Ltd</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortorder="7">Discovery</DevelopmentStatus><Indication id="2989">Kidney transplant rejection</Indication><StatusDate>2014-01-02T00:00:00Z</StatusDate><SourceLink type="PR" id="1512632"/></Row><Row><Company id="15957">Santarus Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DR" sortorder="7">Discovery</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2010-09-13T00:00:00Z</StatusDate><SourceLink type="PR" id="1130308"/></Row><Row><Company id="15957">Santarus Inc</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="DR" sortorder="7">Discovery</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2010-09-13T00:00:00Z</StatusDate><SourceLink type="PR" id="1130308"/></Row><Row><Company id="15957">Santarus Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortorder="7">Discovery</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2010-09-13T00:00:00Z</StatusDate><SourceLink type="PR" id="1130308"/></Row><Row><Company id="15957">Santarus Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortorder="7">Discovery</DevelopmentStatus><Indication id="2989">Kidney transplant rejection</Indication><StatusDate>2010-09-13T00:00:00Z</StatusDate><SourceLink type="PR" id="1130308"/></Row><Row><Company id="1010384">Shanghai Institute of Pharmaceutical Industry</Company><Country id="CN">China</Country><DevelopmentStatus id="DR" sortorder="7">Discovery</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2013-07-01T00:00:00Z</StatusDate><SourceLink type="PR" id="1446251"/></Row><Row><Company id="28921">Swedish Orphan Biovitrum AB</Company><Country id="AZ">Azerbaijan</Country><DevelopmentStatus id="DR" sortorder="7">Discovery</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2014-10-13T00:00:00Z</StatusDate><SourceLink type="PR" id="1696826"/></Row><Row><Company id="28921">Swedish Orphan Biovitrum AB</Company><Country id="BY">Belarus</Country><DevelopmentStatus id="DR" sortorder="7">Discovery</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2014-10-13T00:00:00Z</StatusDate><SourceLink type="PR" id="1696826"/></Row><Row><Company id="28921">Swedish Orphan Biovitrum AB</Company><Country id="GE">Georgia</Country><DevelopmentStatus id="DR" sortorder="7">Discovery</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2014-10-13T00:00:00Z</StatusDate><SourceLink type="PR" id="1696826"/></Row><Row><Company id="28921">Swedish Orphan Biovitrum AB</Company><Country id="KZ">Kazakhstan</Country><DevelopmentStatus id="DR" sortorder="7">Discovery</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2014-10-13T00:00:00Z</StatusDate><SourceLink type="PR" id="1696826"/></Row><Row><Company id="28921">Swedish Orphan Biovitrum AB</Company><Country id="RU">Russian Federation</Country><DevelopmentStatus id="DR" sortorder="7">Discovery</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2014-10-13T00:00:00Z</StatusDate><SourceLink type="PR" id="1696826"/></Row><Row><Company id="28921">Swedish Orphan Biovitrum AB</Company><Country id="RS">Serbia</Country><DevelopmentStatus id="DR" sortorder="7">Discovery</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2014-10-13T00:00:00Z</StatusDate><SourceLink type="PR" id="1696826"/></Row><Row><Company id="28921">Swedish Orphan Biovitrum AB</Company><Country id="UA">Ukraine</Country><DevelopmentStatus id="DR" sortorder="7">Discovery</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2014-10-13T00:00:00Z</StatusDate><SourceLink type="PR" id="1696826"/></Row><Row><Company id="26342">Pharming NV</Company><Country id="BE">Belgium</Country><DevelopmentStatus id="S" sortorder="6">Suspended</DevelopmentStatus><Indication id="156">Hereditary angioedema</Indication><StatusDate>2001-08-30T00:00:00Z</StatusDate><SourceLink type="CORPORATE" id="420400"/></Row></DevelopmentStatusHistoric></Drug></Drugs>